Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors (Q42252644)

19 October 2017

title

Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors (English)

1 reference

19 October 2017

3

1 reference

19 October 2017

M Wang

1

1 reference

19 October 2017

M Zhong

series ordinal

2

1 reference

19 October 2017

L Li

series ordinal

4

1 reference

19 October 2017

C Yu

series ordinal

5

1 reference

19 October 2017

publication date

28 November 2013

1 reference

SAR and QSAR in Environmental Research

19 October 2017

published in

1 reference

19 October 2017

volume

25

1 reference

19 October 2017

issue

1

1 reference

19 October 2017

page(s)

1-15

1 reference

5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Classification of HCV NS5B polymerase inhibitors using support vector machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Prediction of biological activity of Aurora-A kinase inhibitors by multilinear regression analysis and support vector machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

QSAR studies on benzene sulfonamide carbonic anhydrase inhibitors: need of hydrophobic parameter for topological modeling of binding constants of sulfonamides to human CA-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

QSAR study of C allosteric binding site of HCV NS5B polymerase inhibitors by support vector machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Self-Organized Formation of Topologically Correct Feature Maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Synthesis and biological activity of heteroaryl 3-(1,1-dioxo-2H-(1,2,4)-benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone derivatives as hepatitis C virus NS5B polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Molecular properties that influence the oral bioavailability of drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

Thirteen Ways to Look at the Correlation Coefficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

The effects of violations of assumptions underlying the t test

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2013.820790

10.1080/1062936X.2013.820790

21 January 2018

Identifiers

DOI

1 reference

19 October 2017

1 reference